Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on November 15, 2017, reporting on events occurring on November 13, 2017. The filing announces the release of financial results for the three and nine months ended September 30, 2017, alongside updates on clinical programs and business highlights.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.01), which is incorporated by reference but not detailed in the body of this 8-K form.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It serves as a notification that such results have been reported and directs readers to the attached press release for comparative data.
Guidance, Outlook, and Risks
Management provided an update on clinical programs and business highlights in the referenced press release. The filing includes a standard disclaimer stating that the information furnished under Item 2.02 and Exhibit 99.01 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.01 press release.
- Review the clinical program updates and business highlights detailed in the press release.
- Confirm the company name is Neuralstem, Inc., as the metadata reference to "Palisade Bio, Inc." appears to be incorrect based on the filing text.
- Note that the financial data in the press release is not legally "filed" for liability purposes under Section 18 of the Exchange Act.